El fabricante estadounidense de medicamentos Moderna llegó a un acuerdo para fabricar medicamentos de ARN mensajero para su uso en China, a pesar de las tensions between Washington and Beijing.
El miércoles, la biotecnológica dijo que habia llegado a un acuerdo con las authoridades de Beijing para investigadora, desarrollar y fabricar medicamentos que “none se exportarán”.
“Cualquier medicamento produced under this agreement will be exclusive to the Chinese people, which face many of the same health challenges that affect other communities and the whole world,” the company said in a statement.
Los fabricantes de medicamentos siguen interesadores in expanding to China, which faces an aging population, higher rates of chronic diseases and health problems derived from an increasingly western diet. The Chinese government has also accelerated the process of approving innovative medicines, making it even more attractive.
“With this announcement, we are taking even more measures to achieve our mission of generating the mayor’s impact on people through the medicines of ARNm”, said the company.
La empresa Moderna, que cotiza en Nueva York, ha sido una de las majores ganadoras de la pandemia de coronavirus después desarrollar su vacuna. It was one of several international drug groups that pressured Beijing to buy its vaccines.
The Financial Times informed last year that the company had rejected a request from the Chinese authorities to hand over the key intellectual property behind its vaccine, which was developed in conjunction with the government of the EU. UU., lo que provocó una ruptura en las negociaciones.
In October Passado, a person close to the Gran China de Moderna team said that the company had “abandoned” its previous efforts to enter Mercado Chino.
With headquarters in Cambridge, Massachusetts, Moderna is trying to exploit the success of its vaccine, which uses a platform based on a genetic code called ARNm to teach the immune system of the body to respond to the virus. Ahora esta usando el codigo para desarolar otros tratamientos, includo il tratamiento del cancer.
Moderna refused to comment on the reports in the Chinese media that the ARNm agreement has a value of 1 million dollars, or on the specific medicines that it intends to develop in China.
Mientras las compañías pharmaceuticas occidentales persiguen sus ambiciones en China, las tensiones de Beijing con varios gobiernos occidentales Han Levado a Algunos Elaborate plane
AstraZeneca has presented planes to expand its business in China and cotizar in Hong Kong in the midst of creacient tensions geopolitics.
